CAMP
CAMP4 Therapeutics Corp
$
4.250
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.600
Open
4.350
VWAP
3.91
Vol
311.87K
Mkt Cap
660.34K
Low
3.500
Amount
1.22M
EV/EBITDA(TTM)
--
Total Shares
1.65M
EV
-21.11M
EV/OCF(TTM)
--
P/S(TTM)
--
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
53.00M
-32.49%
-2.070
-250%
54.00M
-23.83%
-1.610
-1420.75%
Estimates Revision
The market is revising No Change the revenue expectations for CalAmp Corp. (CAMP) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 197.20%.
Revenue Estimates for FY2024
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2024
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+197.20%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast CAMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAMP is 15.25 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.250
Low
8.00
Averages
15.25
High
18.00
Current: 4.250
Low
8.00
Averages
15.25
High
18.00
JPMorgan
Anupam Rama
Overweight -> Neutral
downgrade
2025-09-16
Reason
JPMorgan
Anupam Rama
Price Target
2025-09-16
downgrade
Overweight -> Neutral
Reason
JPMorgan analyst Anupam Rama downgraded Camp4 Therapeutics to Neutral from Overweight without a price target. The company's private placement provides a cash runway into 2027, but this is balanced by its the lead program CMP-SYNGAP-01 for Syngap-related disorders being in the very early stage, the analyst tells investors in a research note. JPMorgan now sees a long time horizon to patient level value creation for the shares.
Piper Sandler
Edward Tenthoff
Overweight
downgrade
$18 -> $12
2025-09-15
Reason
Piper Sandler
Edward Tenthoff
Price Target
$18 -> $12
2025-09-15
downgrade
Overweight
Reason
Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Camp4 Therapeutics to $12 from $18 and keeps an Overweight rating on the shares. The firm notes Camp4 recently raised $50M bringing pro-form cash to about $86.1M to fund operations into 2027. Participating investors agreed to purchase an additional $50M upon acceptance of the CTA for CPS-SYNGAP-01, which Piper expects in the second half of 2026. The firm is lowering its price target on the shares by increasing value for CMP-SYNGAP-01, reducing value for CMP-CPS-001 and factoring dilution from the recent financing.
Wedbush
NULL -> Outperform
initiated
$8
2025-05-27
Reason
Wedbush
Price Target
$8
2025-05-27
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target.
Wedbush
Yun Zhong
Outperform
initiated
$8
2025-05-27
Reason
Wedbush
Yun Zhong
Price Target
$8
2025-05-27
initiated
Outperform
Reason
Wedbush analyst Yun Zhong initiated coverage of Camp4 Therapeutics with an Outperform rating and $8 price target. The company's lead candidate CMP-CPS-01 increases the expression of an enzyme for the treatment of urea cycle disorders that affect approximately 20,000 U.S. and European Union patients with no disease modifying treatments available, the analyst tells investors in a research note. The firm says preclinical data show efficient and sustained reduction of ammonia, the root cause of all disease symptoms, and increased expression of additional urea cycle enzymes as well, suggesting approximately 90% of urea cycle disorders patients will be eligible for treatment. Wedbush's calculation suggests approximately 2,000 such patients in the U.S., indicating a $1B opportunity.
See All Ratings
Valuation Metrics
The current forward P/E ratio for CAMP4 Therapeutics Corp (CAMP.O) is 0.04, compared to its 5-year average forward P/E of 7.56. For a more detailed relative valuation and DCF analysis to assess CAMP4 Therapeutics Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
7.56
Current PE
0.04
Overvalued PE
150.52
Undervalued PE
-135.40
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
15.72
Current EV/EBITDA
8.16
Overvalued EV/EBITDA
20.60
Undervalued EV/EBITDA
10.84
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
0.62
Current PS
0.00
Overvalued PS
1.10
Undervalued PS
0.14
Financials
Annual
Quarterly
FY2025Q1
YoY :
-98.79%
858.00K
Total Revenue
FY2025Q1
YoY :
+450.42%
-13.10M
Operating Profit
FY2025Q1
YoY :
+208.36%
-12.43M
Net Income after Tax
FY2025Q1
YoY :
+463.64%
-0.62
EPS - Diluted
FY2025Q1
YoY :
+194.96%
-14.57M
Free Cash Flow
FY2025Q1
YoY :
+174.35%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
YoY :
+25366.96%
-1.45K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
7
8.6M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
2.1M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
7
8.6M
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CAMP News & Events
Events Timeline
2025-10-01 (ET)
2025-10-01
08:09:47
Camp4 Therapeutics Begins GLP Toxicology Studies for CMP-SYNGAP-01
2025-09-10 (ET)
2025-09-10
07:12:16
Camp4 Therapeutics names Doug Williams as board chair and Dan Tardiff as Chief Scientific Officer.
2025-09-10
07:11:28
Camp4 Therapeutics Reveals Successful Oversubscribed Private Placement of Up to $100 Million
Sign Up For More Events
Sign Up For More Events
News
9.0
10-01NewsfilterCAMP4 Therapeutics Begins GLP Toxicology Testing for CMP-SYNGAP-01
4.0
09-25NASDAQ.COMCAMP4 Therapeutics Corporation (CAMP) Receives Upgrade to Buy: Key Information You Need to Know
4.0
09-16BenzingaJP Morgan Lowers Camp4 Therapeutics Rating to Neutral
Sign Up For More News
People Also Watch
VOR
Vor Biopharma Inc
18.700
USD
-1.42%
SHIM
Shimmick Corp
2.050
USD
-5.40%
BKHA
Black Hawk Acquisition Corp
11.370
USD
+1.52%
ALXO
ALX Oncology Holdings Inc
1.380
USD
+16.95%
MLSS
Milestone Scientific Inc
0.400
USD
+2.56%
ASMB
Assembly Biosciences Inc
31.200
USD
-0.03%
CODA
Coda Octopus Group Inc
9.100
USD
+2.94%
ORMP
Oramed Pharmaceuticals Inc
2.190
USD
-0.45%
FAQ
What is CAMP4 Therapeutics Corp (CAMP) stock price today?
The current price of CAMP is 4.25 USD — it has decreased -4.49 % in the last trading day.
What is CAMP4 Therapeutics Corp (CAMP)'s business?
What is the price predicton of CAMP Stock?
What is CAMP4 Therapeutics Corp (CAMP)'s revenue for the last quarter?
What is CAMP4 Therapeutics Corp (CAMP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for CAMP4 Therapeutics Corp (CAMP)'s fundamentals?
How many employees does CAMP4 Therapeutics Corp (CAMP). have?